Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
July 2017

Valbenazine (Ingrezza): The First Drug Approved to Treat TD
Valbenazine (Ingrezza), an inhibitor of vesicular monoamine transporter 2 (VMAT2), is the first medication approved by the FDA to treat tardive dyskinesia.

A Dietary Supplement to Reduce the Risk of Postpartum Depression?
In a small, open-label trial, a dietary supplement decreased the propensity for sadness in postpartum women.

Pimavanserin (Nuplazid) for Parkinson Disease Psychosis
Pimavanserin (Nuplazid), a new molecular entity, is the first drug approved by the FDA to treat Parkinson disease psychosis.

In Brief
Review Finds that Dietary Supplements and Special Diets Do Not Improve Autism Symptoms; Aerobic Exercise Improves Executive Function in Adults with Vascular Cognitive Impairment

Don't Forget Clozapine
A recent survey found that US residents are hesitant to prescribe clozapine (Clozaril and others) for patients with schizophrenia, citing fear of side effects and lack of sufficient training on how to properly prescribe and monitor clozapine treatment.

Affiliated Links

The Journal of Clinical Psychiatry

The University of Arizona Health Sciences Center- Department of Psychiatry

American Academy of Child and Adolescent Psychiatry

American Association of Suicidology

American Psychiatric Association

American Society for Adolescent Psychiatry

American Society of Addiction Medicine

American Society of Clinical Psychopharmacology

Autism Society of America

Depression and Bipolar Support Alliance (DBSA)

National Alliance for Research on Schizophrenia and Depression (NARSAD)

National Alliance for the Mentally Ill

National Association of Alcoholism and Drug Abuse Counselors

National Institute of Mental Health

National Mental Health Association